AMAG News and Press, AMAG Pharmaceuticals Inc. From 09/30/20

Gainers: [[AMAG]] +39.4%. [[DNOW]] +9.9%. [[DTIL]] +5.5% [[MNOV]] +5.0%. [[ODT]] +4.5%.Losers: [[LOGC]] -25.1%. [[SPI]] -15.6%. [[AMBO]] -5.9%. [[NG]] -5.9%. [[cc]] -4.3%. For further details see: AMAG, ODT, SPI and NG among after-hours movers

AMAG Pharmaceuticals (AMAG) jumps 41% after hours in apparent response to rumors that Apollo Global Management portfolio company Covis Pharma is about to acquire the company.The company sells two products: Makena (hydroxyprogesterone caproate injection) for reducing the risk of pret...

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22 nd Annual Global Investment ...

AMAG Pharmaceuticals, Inc. (AMAG) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 ET Company Participants Rushmie Nofsinger - Executive Director, Corporate Communications & Alliance Engagement Scott Myers - President, CEO & Director Anthony Casciano - EVP & CO...

Image source: The Motley Fool. AMAG Pharmaceuticals Inc   (NASDAQ: AMAG) Q2 2020 Earnings Call Aug 6, 2020 , 8:00 a.m. ET Operator Continue reading

AMAG Pharmaceuticals (NASDAQ: AMAG ) : Q2 GAAP EPS of -$0.39 beats by $0.10 . More news on: AMAG Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Financial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activities Brian Piekos promoted to Chief Financial Officer Conference call scheduled for 8:00 a.m. ET today WALTHAM...

WALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S. financial markets open. Management will host a conference call and webcast ...

Palatin Technologies (NYSEMKT: PTN )   jumps 10%  premarket after terminating  January 2017 license agreement with AMAG Pharmaceuticals (NASDAQ: AMAG ) , which granted latter exclusive rights to develop and commercialize Vyleesi (bremelanotide), a melanocortin rec...

Vyleesi® returned to Palatin Technologies Company focuses on optimizing marketed assets and development of its innovative pipeline WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) --  AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technolog...